Generate:Biomedicines announced plans to start Phase 3 studies for its lead TSLP (thymic stromal lymphopoietin) antibody, marking a major clinical milestone for the AI-enabled biotech. The company framed the move as validation of its discovery engine and clinical translation pathway. The Phase 3 launch will test the antibody in indications where TSLP is implicated in type 2 inflammation. For AI‑driven discovery firms, a Phase 3 transition is a critical proof point for platform‑to‑clinic credibility.